Peter Merkel, MD
Rheumatology · Radnor, PANPI 1437136173
Payments from drug & device makers
Across 310 payments — averaging $20,472 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2.7M
- AstraZeneca$2.3M
- AbbVie$407K
- E.r. Squibb & Sons, L.L.C.$355K
- Astrazeneca UK Limited$121K
- NS Pharma, Inc.$97K
- plus $364K from 23 others
Across 5 payments — averaging $2078.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$5K
- Amgen$3K
- Argenx US, Inc.$2K
- AbbVie$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 36 | $2,735,891 |
| AstraZeneca(2 entities) | 49 | $2,266,814 |
| AbbVie | 26 | $406,925 |
| E.r. Squibb & Sons, L.L.C. | 23 | $354,637 |
| Astrazeneca UK Limited | 36 | $120,943 |
| NS Pharma, Inc. | 15 | $96,717 |
| Amgen | 28 | $86,512 |
| Genentech, Inc. | 5 | $75,502 |
| Sanofi US Services Inc. | 11 | $59,433 |
| Bristol Myers Squibb | 9 | $22,178 |
| Novartis Pharma AG | 5 | $20,808 |
| CSL Behring | 7 | $19,254 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | $12,988 |
| Boehringer Ingelheim | 11 | $11,926 |
| Astrazeneca AB | 5 | $10,034 |
| Argenx US, Inc. | 6 | $9,675 |
| Sanofi | 3 | $7,635 |
| Boehringer Ingelheim International GmbH | 8 | $5,574 |
| Novartis | 1 | $4,200 |
| F. Hoffmann-la Roche AG | 3 | $4,064 |
| Chugai Pharmaceutical Co., Ltd. | 2 | $3,640 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $3,575 |
| Mallinckrodt Hospital Products Inc. | 1 | $3,000 |
| Regeneron | 3 | $1,668 |
| Eli Lilly | 1 | $1,200 |
| Jubilant Therapeutics Inc | 1 | $825 |
| EMD Serono, Inc. | 1 | $530 |
| Johnson & Johnson | 1 | $55 |
| Genentech USA, Inc. | 1 | $10 |
How this compares
$6,346,212 in reported general payments places this provider in the 95th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Radnor
- Alan KivitzDuncansville$27.1M
- Rohit AggarwalPittsburgh$6.2M
- Alexis Ogdie-BeattyPhiladelphia$5.7M
- Jonathan MinerPhiladelphia$3.8M
- Siamak Moghadam-KiaPittsburgh$1.9M
- Frederick MurphyDuncansville$1.2M
- Gregory EmkeyWyomissing$1.2M
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
- Paula HerringNewtown Square$920K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.